Straits Times Index
3,297.32 -7.67 (-0.23%) Nikkei
38,782.08 -138.18 (-0.36%) Hang Seng
19,398.90 +22.37 (+0.12%) FTSE 100
8,438.65 -7.15 (-0.08%) Bitcoin USD
65,640.95 -413.89 (-0.63%) CMC Crypto 200
1,376.55 -17.50 (-1.26%)
SNY Jan 2025 50.000 call
| Previous close | 4.1200 |
| Open | 4.1700 |
| Bid | 3.4000 |
| Ask | 4.8000 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.1200 - 4.1700 |
| Contract range | N/A |
| Volume | |
| Open interest | 272 |
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
BenzingaPfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
FX EmpireNovavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
The past five days have been a rollercoaster for Novavax investors, as the share price of the company skyrocketed by over 200% following the announcement of a major deal with French pharmaceutical giant Sanofi.
